DelveInsight’s “Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC), historical and forecasted epidemiology as well as the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some facts of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market:
- The highest number of NSCLC Cases were estimated in the United States.
- According to DelveInsight’s assessment, in the United States, 7 out of 10 patients had metastatic NSCLC (Stage IIIb and IV).
- The United States had 227,875 incident cases of Lung Cancer in 2020, of which ~85% were NSCLC cancer patient (GLOBOCAN, n.d..)
- Among the European 5 countries, the Germany had highest cases of NSCLC. Furthermore, Japan accounts for about 117,752 cases in 2020.
- DelveInsight’s analysts have estimated that in 2020, in the United States there were over 38,000 incident cases for EGFR mutation.
Request for Sample Report: https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market
Scope of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Report
- The report covers the descriptive overview of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market
NSCLC is the most common type of lung cancer and metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells. Recent advances in understanding of cell signalling pathways that control cell survival have identified genetic and regulatory aberrations that suppress cell death, promote cell division, and induce tumorogenesis. One such discovery is that of epidermal growth factor receptor (EGFR). EGFR is a transmembrane receptor tyrosine kinase protein that is expressed in some normal epithelial, mesenchymal, and neurogenic tissue. Overexpression of EGFR has been reported and implicated in the pathogenesis of many human malignancies, including NSCLC. The EGFR gene may also undergo amplification, as detected by fluorescence in situ hybridization (FISH) or chromogenic in situ hybridization (CISH).
Request for Sample Report: https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market
Some of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Companies are:
- Takeda
- Yuhan Corporation
- Janssen Research & Development
- Novartis
- Daiichi Sankyo
- Astellas
- Astrazeneca
- And Many Others
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Therapies covered:
- TAK-788 (mobocertinib)
- Lazertinib (Leclaza)
- Nazartinib (EGF816)
- Patritumab deruxtecan (HER3-DXd)
- And Many Others
Table of Contents:
1. Key Insights
2. Executive Summary of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)
3. Competitive Intelligence Analysis for Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)
4. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC): Market Overview at a Glance
5. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC): Disease Background and Overview
6. Patient Journey
7. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Unmet Needs
10. Key Endpoints of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Treatment
11. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Marketed Products
List to be continued in report
12. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Emerging Therapies
13. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Other Reports:
DelveInsight’s ‘Deep Vein Thrombosis – Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Deep Vein Thrombosis and the historical and forecasted Deep Vein Thrombosis market trends, globally, which comprises of North America, Europe, APAC, and RoW.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market